MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Search

TransMedics Group Inc

Abrir

SetorSaúde

115.54 0.18

Visão Geral

Variação de preço das ações

24h

Atual

Mín

115

Máximo

119.6

Indicadores-chave

By Trading Economics

Rendimento

9.2M

35M

Vendas

14M

157M

P/E

Médio do Setor

57.178

35.739

Margem de lucro

22.181

Funcionários

728

EBITDA

10M

46M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+22.82% upside

Dividendos

By Dow Jones

Próximos Ganhos

27 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

321M

3.9B

Abertura anterior

115.36

Fecho anterior

115.54

Sentimento de Notícias

By Acuity

26%

74%

61 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

TransMedics Group Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de ago. de 2025, 19:15 UTC

Grandes Movimentos do Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Comparação entre Pares

Variação de preço

TransMedics Group Inc Previsão

Preço-alvo

By TipRanks

22.82% parte superior

Previsão para 12 meses

Média 142.56 USD  22.82%

Máximo 170 USD

Mínimo 115 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para TransMedics Group Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

8

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

92.43 / 94.18Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

61 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat